AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Nasal vaccine controls SHIV viremia and disease progression in primates.
2004 MAY 5 - (NewsRx.com & NewsRx.net) -- IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination controlled simian/human immunodeficiency virus viremia and disease progression in nonhuman primates.
According to recent research from the United States, "A successful HIV vaccine may need to stimulate antiviral immunity in mucosal and systemic immune compartments, because HIV transmission occurs predominantly at mucosal sites. We report here the results of a combined DNA-modified vaccinia virus Ankara (MVA) vaccine approach that stimulated simian/human immunodeficiency virus (SHIV)-specific immune responses by vaccination at the nasal mucosa. Fifteen male rhesus macaques, divided into three groups, received three nasal vaccinations on day 1, week 9, and week 25 with a SHIV DNA plasmid producing noninfectious viral particles (group 1), or SHIV DNA plus IL-2/Ig DNA (group 2), or SHIV DNA plus IL-12 DNA (group 3).
"On week 33, all macaques were boosted with rMVA expressing SIV Gag-Pol and HIV Env 89.6P, administered nasally," reported Frederic M. N. Bertley and collaborators at Harvard University and Duke University. "Humoral responses were evaluated by measuring SHIV-specific IgG and neutralizing antibodies in plasma, and SHIV-specific IgA in rectal secretions. Cellular responses were monitored by evaluating blood-derived virus-specific IFN-gamma-secreting cells and TNF-alpha-expressing CD8+ T cells, and blood- and rectally derived p11C tetramer-positive T cells.
"Many of the vaccinated animals developed both mucosal and ...
- Nasal vaccine controls SHIV viremia and disease progression in primates.
- Newspaper article from: Drug Week May 7, 2004 700+ words
...virus viremia and disease progression in nonhuman primates...and week 25 with a SHIV DNA plasmid producing...particles (group 1), or SHIV DNA plus IL-2/Ig DNA...nasal vaccination with SHIV-DNA plus IL-2/Ig DNA...significant protection from disease ...
- Researchers Report That Oral Phenoxodiol Slows Disease Progression in...
- Press release article from: PR Newswire November 22, 2004 700+ words
...of phenoxodiol on PSA levels and disease progression. The main purpose of the study...continued for 6 months or until disease progression. Patients who were considered to...continued on 200 mg phenoxodiol until disease progression. About the results Phenoxodiol...
- Dynamic load at baseline can predict radiographic disease progression in medial...
- Magazine article from: Annals of the Rheumatic Diseases Miyazaki, T Wada, M Kawahara, H Sato, M Baba, H Shimada, S July 1, 2002 700+ words
...baseline can predict radiographic disease progression in patients with medial compartment...radiographic changes. Radiographic disease progression was defined as more than one grade...Results: In the 32 patients showing disease progression, pain was more severe and adduction...
- Sequencing the lifetime onset of alcohol-related symptoms in older adults: is...
- Magazine article from: Journal of Studies on Alcohol Lemke, Sonne Schutte, Kathleen K. Brennan, Penny L. Moos, Rudolf H. November 1, 2005 700+ words
...can be characterized in terms of a disease-progression model, which specifies that symptoms...has progressed. If confirmed, a disease-progression model has the potential to improve...issue in assessing evidence for a disease-progression model is whether an accurate general...
- Immunological and virological markers of HIV-disease progression.
- Magazine article from: Journal of the Association of Nurses in AIDS Care Zeller, Janice M. McCain, Nancy L. Swanson, Barbara January 1, 1996 700+ words
...also holds promise for following disease progression. It is recommended that a combination...infected persons. Key words: HIV disease progression, immune markers, virological markers...process, change in response to disease progression from symptomless early HIV infection...
- CD4 Lymphocyte Percentage and HIV Disease Progression.
- Magazine article from: Infectious Disease Alert December 1, 2005 700+ words
...CD4 Lymphocyte Percentage and HIV Disease Progression Abstract & Commentary By Dean...lymphocyte percentage predicted disease progression in patients who initiated antiretroviral...CD4 Lymphocyte Percentage Predicts Disease Progression in HIV-Infected Patients Initiating...
- RAPID DISEASE PROGRESSION FOLLOWING ACUTE INFECTION BY POLYTROPIC HIV-1.(Brief...
- Magazine article from: Journal of the Alabama Academy of Science January 1, 2000 700+ words
RAPID DISEASE PROGRESSION FOLLOWING ACUTE INFECTION BY...is a cause or an effect of disease progression is not known. Patient WEAU...rapid CD4+ cell decline and disease progression to AIDS and death. A unique...
- EPIVIR (LAMIVUDINE; 3TC) STUDY STOPPED; RESULTS SHOW SIGNIFICANT REDUCTION IN...
- Press release article from: PR Newswire July 23, 1996 700+ words
...lamivudine; 3TC) on survival, delay in disease progression or both, has been stopped after...percent reduction in the rate of HIV disease progression, or death, for HIV patients who...to placebo. The endpoint event (disease progression or death) rate in the regimen containing...
- Eli Lilly and Company: Gemzar Combination Delays Disease Progression In...
- Press release article from: Business Wire June 1, 2003 700+ words
...efficacy of Taxol in delaying time to disease progression among patients with metastatic breast...following results: -- Median time to disease progression, the primary interim endpoint of...significant (p= 0.0013). Time to disease progression is a measure of time after cancer...
- REVLIMID(R) (lenalidomide) Significantly Delays Time to Disease Progression in...
- Press release article from: PR Newswire May 16, 2005 700+ words
...Symposium - The median time-to-disease progression in the North American Phase III...compared with the median time-to-disease progression of 20.7 weeks for placebo plus...00000000000001) - The median time-to-disease progression in the International Phase III Trial...
Source: HighBeam Research, Nasal vaccine controls SHIV viremia and disease progression in...